Literature DB >> 34857613

Comorbid insomnia and sleep apnoea is associated with all-cause mortality.

Bastien Lechat1,2, Sarah Appleton2, Yohannes Adama Melaku2, Kristy Hansen3, R Doug McEvoy2,4, Robert Adams2,4, Peter Catcheside2, Leon Lack4,5, Danny J Eckert2, Alexander Sweetman2,4.   

Abstract

BACKGROUND: Increased mortality has been reported in people with insomnia and in those with obstructive sleep apnoea (OSA). However, these conditions commonly co-occur and the combined effect of comorbid insomnia and sleep apnoea (COMISA) on mortality risk is unknown. This study used Sleep Heart Health Study (SHHS) data to assess associations between COMISA and all-cause mortality risk.
METHODS: Insomnia was defined as difficulties falling asleep, maintaining sleep and/or early morning awakenings from sleep ≥16 times per month, and daytime impairments. OSA was defined as an apnoea-hypopnoea index ≥15 events·h-1. COMISA was defined if both conditions were present. Multivariable adjusted Cox proportional hazards models were used to determine the association between COMISA and all-cause mortality (n=1210) over 15 years of follow-up.
RESULTS: 5236 participants were included. 2708 (52%) did not have insomnia/OSA (reference group), 170 (3%) had insomnia-alone, 2221 (42%) had OSA-alone and 137 (3%) had COMISA. COMISA participants had a higher prevalence of hypertension (OR 2.00, 95% CI 1.39-2.90) and cardiovascular disease (CVD) (OR 1.70, 95% CI 1.11-2.61) compared with the reference group. Insomnia-alone and OSA-alone were associated with higher risk of hypertension but not CVD compared with the reference group. Compared with the reference group, COMISA was associated with a 47% (hazard ratio 1.47, 95% CI 1.06-2.07) increased risk of mortality. The association between COMISA and mortality was consistent across multiple definitions of OSA and insomnia.
CONCLUSIONS: COMISA was associated with higher rates of hypertension and CVD at baseline, and an increased risk of all-cause mortality compared with no insomnia/OSA.
Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.

Entities:  

Mesh:

Year:  2022        PMID: 34857613     DOI: 10.1183/13993003.01958-2021

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   33.795


  5 in total

1.  Insomnia and Upper Airway Stimulation Therapy Benefit and Adherence: A Case Series.

Authors:  Stephanie M Stahl; Shalini Manchanda; Noah Parker; Yelena Chernyak
Journal:  J Clin Psychol Med Settings       Date:  2022-06-06

Review 2.  More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea.

Authors:  Johan Verbraecken
Journal:  Curr Opin Pulm Med       Date:  2022-09-14       Impact factor: 2.868

3.  Brazilian Thoracic Association Consensus on Sleep-disordered Breathing.

Authors:  Ricardo Luiz de Menezes Duarte; Sonia Maria Guimarães Pereira Togeiro; Luciana de Oliveira Palombini; Fabíola Paula Galhardo Rizzatti; Simone Chaves Fagondes; Flavio José Magalhães-da-Silveira; Marília Montenegro Cabral; Pedro Rodrigues Genta; Geraldo Lorenzi-Filho; Danielle Cristina Silva Clímaco; Luciano Ferreira Drager; Vitor Martins Codeço; Carlos Alberto de Assis Viegas; Marcelo Fouad Rabahi
Journal:  J Bras Pneumol       Date:  2022-07-08       Impact factor: 2.800

4.  All-Cause Mortality in People with Co-Occurring Insomnia Symptoms and Sleep Apnea: Analysis of the Wisconsin Sleep Cohort.

Authors:  Bastien Lechat; Kelly A Loffler; Douglas M Wallace; Amy Reynolds; Sarah L Appleton; Hannah Scott; Andrew Vakulin; Nicole Lovato; Robert Adams; Danny J Eckert; Peter G Catcheside; Alexander Sweetman
Journal:  Nat Sci Sleep       Date:  2022-10-13

5.  Association of self-reported snoring with decreased retinal thickness and vessel density.

Authors:  Yunfan Xiao; Keai Shi; Chunmei Li; Kai Yang; Xiaoxuan Zhu; Binbin Su; Ying Ju; Fan Lu; Jia Qu; Ming Li; Lele Cui
Journal:  Front Physiol       Date:  2022-08-05       Impact factor: 4.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.